Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | CHIEF COMMERCIAL OFFICER | March 03, 2025 | March 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harmony Biosciences Holdings, Inc.
Report date March 03, 2025 · Filed March 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-03-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-03-03 · Exercise / conversion · Acquired 4,869 · Balance 4,869 Row 2 · 2025-03-03 · Sale · Disposed 4,369 · Balance 500 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.08 to $32.97. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2025-03-03 · Sale · Disposed 500 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.14 to $33.39. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.22 · Expires 2030-03-04 | Direct | 0 |
Reported balance
After 2025-03-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-03-03 · Exercise / conversion · Disposed 4,869 · Balance 0 F4: The stock option vests in five equal annual installments beginning on March 1, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.08 to $32.97. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.14 to $33.39. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The stock option vests in five equal annual installments beginning on March 1, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2021 Filed Aug 30, 2021 20:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 3,400 | $8.22 | $27,948.00 |
DisclosureSEC source: 0000899243-21-034515 · doc4.xml · nonDerivative · entry 3 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 20:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 1,600 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0000899243-21-034515 · doc4.xml · derivative · entry 5 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,092 Underlying: Common Stock · 1,600 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is currently vested with respect to 20,707 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 2, 2021. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 20:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 1,600 | $35.01 | $56,021.28 |
DisclosureSEC source: 0000899243-21-034515 · doc4.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.045. The reporting person undertakes to provide the issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 20:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 1,600 | $8.22 | $13,152.00 |
DisclosureSEC source: 0000899243-21-034515 · doc4.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 22:13 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 15,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0000899243-21-024214 · doc4.xml · derivative · entry 3 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,692 Underlying: Common Stock · 15,000 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is currently vested with respect to 20,707 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 2, 2021. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 22:13 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 15,000 | $31.32 | $469,806.00 |
DisclosureSEC source: 0000899243-21-024214 · doc4.xml · nonDerivative · entry 2 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.96 to $31.73. The reporting person undertakes to provide the issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 22:13 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 15,000 | $8.22 | $123,300.00 |
DisclosureSEC source: 0000899243-21-024214 · doc4.xml · nonDerivative · entry 1 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2021 Filed Jun 15, 2021 21:13 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 53,900 | $0.00 Strike: $33.44 | $0.00 |
DisclosureSEC source: 0000899243-21-023896 · doc4.xml · derivative · entry 1 Dierks Jeffrey · CIK 0001821102 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,900 Underlying: Common Stock · 53,900 shares Expires 2031-06-01 F1 · derivative.exercise_date: The stock option shall vest with respect to half of the underlying shares on June 1, 2022 and with respect to the remaining shares, in forty-eight equal monthly installments beginning on July 1, 2022. Read SEC document |
| August 18, 2020 Filed Aug 21, 2020 00:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 144,856 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023131 · doc4.xml · derivative · entry 1 Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,856 Underlying: Common Stock · 144,856 shares Expires 2030-08-18 F1 · derivative.exercise_date: The stock option shall vest in five equal annual installments beginning on August 21, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.